Who Supplies Fenofibrate to India from AUSTRALIA

Importing finished pharmaceutical formulations containing Fenofibrate (HS Code 30049099) into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each product batch must be registered with the CDSCO, which involves submitting Form 40 or 41, depending on the product's classification. The registration process includes providing detailed product information, manufacturing details, and stability data. The timeline for obtaining CDSCO approval varies but typically ranges from 6 to 12 months, depending on the completeness of the application and the product's classification. For formulations containing Fenofibrate, specific requirements include demonstrating therapeutic efficacy, safety, and compliance with the Indian Pharmacopoeia standards.

Imported Fenofibrate formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product efficacy and safety under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. Any discrepancies or failures in quality testing can lead to the rejection of the batch and potential penalties for the importer.

Between 2024 and 2026, the Indian government has implemented several regulatory updates affecting pharmaceutical imports. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements with Australia have been strengthened, facilitating smoother trade and potentially offering preferential treatment for Australian pharmaceutical products. These developments aim to balance the promotion of domestic industry with the need for high-quality imported formulations.

India imports finished Fenofibrate formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic capacity for manufacturing certain Fenofibrate formulations is limited, leading to reliance on imports to fulfill market needs. The market size for Fenofibrate formulations in India is substantial, with a growing patient population requiring lipid-lowering therapies. Imports play a crucial role in ensuring the availability of these essential medications.

The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 11%. The Goods and Services Tax (GST) at the Integrated Goods and Services Tax (IGST) rate is applicable, with the exact rate depending on the product classification. Exemptions or concessional rates may apply under specific Free Trade Agreements (FTAs) or bilateral agreements. Anti-dumping duties are not currently imposed on Fenofibrate formulations. The total landed duty percentage varies based on the product's value and applicable exemptions.

India sources Fenofibrate formulations from Australia due to the high quality and compliance with international standards. Australian manufacturers offer patented formulations and specialized dosage forms that are not readily available from other suppliers. While countries like China, Germany, and the United States also supply Fenofibrate formulations, Australia's reputation for quality and regulatory compliance provides a competitive advantage. Australia's share in the Indian market is significant, reflecting the trust and demand for its pharmaceutical products.

India imports Fenofibrate formulations from Australia due to the availability of patented products, specialized dosage forms, and high-quality manufacturing standards. Australian manufacturers offer formulations that are not produced domestically, fulfilling specific market needs. The trust in Australian pharmaceutical products' safety and efficacy further drives imports.

Compared to other origins like China, the European Union, and the United States, Australia offers a competitive advantage in terms of product quality, regulatory compliance, and innovation. While other countries may offer lower prices, Australia's adherence to international standards and the availability of unique formulations justify the higher cost for Indian importers.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. Past shortages have been minimal, but importers should monitor the supply chain for any emerging risks.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage cash flow.
4. 4Minimum Order Quantities (MOQs): Align procurement volumes with market demand to optimize costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

1. 1Obtain Directorate General of Foreign Trade (DGFT) Importer License.
2. 2Register the product with CDSCO using Form 40 or 41.
3. 3Provide a No Objection Certificate (NOC) from the manufacturer.
4. 4Engage a Customs House Agent (CHA) for customs clearance.
5. 5Seek an advance ruling for HS Code 30049099 if necessary.

1. 1Certificate of Analysis (CoA).
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.

4.